Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.

× No keyword cloud information.

11 in total

1. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

Authors: D Elias; F Blot; A El Otmany; S Antoun; P Lasser; V Boige; P Rougier; M Ducreux
Journal: Cancer Date: 2001-07-01 Impact factor: 6.860

2. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion.

Authors: H Mahteme; I Wallin; B Glimelius; L Påhlman; H Ehrsson
Journal: Eur J Clin Pharmacol Date: 2008-06-18 Impact factor: 2.953

3. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.

Authors: P Pfeiffer; H Sørbye; H Ehrsson; T Fokstuen; J P Mortensen; L Baltesgard; K M Tveit; D Øgreid; H Starkhammar; I Wallin; C Qvortrup; B Glimelius
Journal: Ann Oncol Date: 2005-11-15 Impact factor: 32.976

4. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).

Authors: Atsushi Yonezawa; Satohiro Masuda; Sachiko Yokoo; Toshiya Katsura; Ken-Ichi Inui
Journal: J Pharmacol Exp Ther Date: 2006-08-16 Impact factor: 4.030

5. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.

Authors: Daniele Santini; Bruno Vincenzi; Annalisa La Cesa; Marco Caricato; Gaia Schiavon; Bruno Spalletta; Marisa Di Seri; Roberto Coppola; Laura Rocci; Giuseppe Tonini
Journal: Oncology Date: 2005-07-28 Impact factor: 2.935

6. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors: P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

7. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.

Authors: Xuemin Jiang; Peter Galettis; Matthew Links; Paul L Mitchell; Andrew J McLachlan
Journal: Br J Clin Pharmacol Date: 2007-10-24 Impact factor: 4.335

8. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.

Authors: Sachiko Yokoo; Atsushi Yonezawa; Satohiro Masuda; Atsushi Fukatsu; Toshiya Katsura; Ken-Ichi Inui
Journal: Biochem Pharmacol Date: 2007-03-12 Impact factor: 5.858

9. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.

Authors: Sachiko Yokoo; Satohiro Masuda; Atsushi Yonezawa; Tomohiro Terada; Toshiya Katsura; Ken-ichi Inui
Journal: Drug Metab Dispos Date: 2008-08-18 Impact factor: 3.922

10. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.

Authors: B L van Leeuwen; W Graf; L Pahlman; H Mahteme
Journal: Ann Surg Oncol Date: 2007-12-05 Impact factor: 5.344